Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
0 competitors in Methicillin-Resistant Staphylococcus Aureus
View Full LandscapeTarget Indication
Methicillin-Resistant Staphylococcus Aureus
Clinical Trial
NCT02814916Last updated: 1/2/2026
No patent data available. Pre-approval drugs may not have Orange Book listings.
Xydalba
Xydalba is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults and paediatric patients from birth (see sections 4.4 and 5.1).Consideration should be given to official guidance on the appropriate use of antibacterial agents.
View on EMA